Evidence map›Paper›PMID 36773936›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2023

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.

Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, Véronique Olislagers, Daphnée Georges, Alexandra Waegemans, Pieter Pannus, Anne Lemy, Maria E Goossens, Isabelle Desombere and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Delphine KemlinInstitute for Medical Immunology and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium; Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium. Electronic address: delphine.kemlin@erasme.ulb.ac.be.
Nicolas GemanderInstitute for Medical Immunology and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Stéphanie DepickèreScientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Véronique OlislagersInstitute for Medical Immunology and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Daphnée GeorgesInstitute for Medical Immunology and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium; Laboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS, University of Liège, Liège, Belgium.
Alexandra WaegemansInstitute for Medical Immunology and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Pieter PannusScientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Anne LemyDepartment of Nephrology, Marie Curie Hospital, Charleroi, Belgium.
Maria E GoossensScientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Isabelle DesombereScientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Johan MichielsDepartment of Biomedical Sciences, Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Marylène VandevenneLaboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS, University of Liège, Liège, Belgium.
Leo HeyndrickxDepartment of Biomedical Sciences, Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Kevin K AriënDepartment of Biomedical Sciences, Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
André MatagneLaboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS, University of Liège, Liège, Belgium.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Alain Le MoineDepartment of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium.
Arnaud MarchantInstitute for Medical Immunology and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium. Electronic address: arnaud.marchant@ulb.be.
Université Libre de Bruxelles · BESciensano (Belgium) · BEInstituut voor Tropische Geneeskunde · BEUniversity of Liège · BEDartmouth College · USHôpital Civil de Charleroi · BEUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As solid organ transplant recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been identified in this vulnerable population. We conducted a prospective monocentric cohort study of 65 kidney transplant recipients who received 3 doses of BNT162b2 mRNA vaccine. Associations among breakthrough infection (BTI), vaccine responses, and patient characteristics were explored in 54 patients. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of 6 months after booster vaccination. During this period, SARS-CoV-2 delta and omicron were the dominant variants in the general population. Univariate Analyses identified the avidity of SARS-CoV-2 receptor binding domain binding IgG, neutralizing antibodies, and SARS-CoV-2 S2-specific interferon gamma responses as correlates of protection against BTI. No demographic or clinical parameter correlated with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing antibody and S2-specific interferon gamma responses. In conclusion, T cell responses may help compensate for the suboptimal antibody response to booster vaccination in kidney transplant recipients. Further studies are needed to confirm these findings.

Indexed as

COVID-19Kidney TransplantationAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineBreakthrough InfectionsCohort StudiesHumansImmunoglobulin GInterferon-gammaProspective StudiesSARS-CoV-2Transplant RecipientsVaccinationAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineImmunoglobulin GInterferon-gammabreakthrough casesCOVID-19immunogenicitykidney transplantationmRNA vaccination

Identifiers

PMID36773936
PMCPMC9911984
OpenAlexW4319968088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.